Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE total assets
Total assets on the balance sheet at the end of each period.
Viridian Therapeutics, Inc.\DE's total assets was $1.10B at Jun 30, 2026. For fiscal 2025 it was $899.42M, up 21.1% from the year before. Over ten years it grew 52.9% a year on average. The highest annual figure on record is $899.42M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $899.42M | +21.1% |
| FY2024 | Dec 31, 2024 | $742.40M | +51.4% |
| FY2023 | Dec 31, 2023 | $490.42M | +12.7% |
| FY2022 | Dec 31, 2022 | $435.09M | +113.6% |
| FY2021 | Dec 31, 2021 | $203.71M | +55.2% |
| FY2020 | Dec 31, 2020 | $131.26M | +333.7% |
| FY2019 | Dec 31, 2019 | $30.26M | -54.3% |
| FY2018 | Dec 31, 2018 | $66.15M | +26.0% |
| FY2017 | Dec 31, 2017 | $52.48M | +112.0% |
| FY2016 | Dec 31, 2016 | $24.76M | +91.9% |
| FY2015 | Dec 31, 2015 | $12.90M | +59.5% |
| FY2014 | Dec 31, 2014 | $8.09M | +120.2% |
| FY2013 | Dec 31, 2013 | $3.67M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.10B | +88.4% |
| Q1 FY2026 | Mar 31, 2026 | $789.02M | +19.4% |
| Q4 FY2025 | Dec 31, 2025 | $899.42M | +21.1% |
| Q3 FY2025 | Sep 30, 2025 | $577.14M | -25.2% |
| Q2 FY2025 | Jun 30, 2025 | $582.32M | -0.6% |
| Q1 FY2025 | Mar 31, 2025 | $660.98M | +4.9% |
| Q4 FY2024 | Dec 31, 2024 | $742.40M | +51.4% |
| Q3 FY2024 | Sep 30, 2024 | $771.90M | +134.8% |
| Q2 FY2024 | Jun 30, 2024 | $585.66M | +66.6% |
| Q1 FY2024 | Mar 31, 2024 | $630.38M | +63.0% |
| Q4 FY2023 | Dec 31, 2023 | $490.42M | +12.7% |
| Q3 FY2023 | Sep 30, 2023 | $328.76M | -25.4% |
| Q2 FY2023 | Jun 30, 2023 | $351.47M | +107.0% |
| Q1 FY2023 | Mar 31, 2023 | $386.64M | +111.1% |
| Q4 FY2022 | Dec 31, 2022 | $435.09M | +113.6% |
| Q3 FY2022 | Sep 30, 2022 | $440.58M | +99.2% |
| Q2 FY2022 | Jun 30, 2022 | $169.81M | +43.7% |
| Q1 FY2022 | Mar 31, 2022 | $183.17M | +49.1% |
| Q4 FY2021 | Dec 31, 2021 | $203.71M | +55.2% |
| Q3 FY2021 | Sep 30, 2021 | $221.21M | +573.7% |
| Q2 FY2021 | Jun 30, 2021 | $118.20M | +253.0% |
| Q1 FY2021 | Mar 31, 2021 | $122.83M | +214.6% |
| Q4 FY2020 | Dec 31, 2020 | $131.26M | +333.7% |
| Q3 FY2020 | Sep 30, 2020 | $32.83M | -15.4% |
| Q2 FY2020 | Jun 30, 2020 | $33.49M | -31.4% |
| Q1 FY2020 | Mar 31, 2020 | $39.05M | -28.9% |
| Q4 FY2019 | Dec 31, 2019 | $30.26M | -54.3% |
| Q3 FY2019 | Sep 30, 2019 | $38.81M | -49.3% |
| Q2 FY2019 | Jun 30, 2019 | $48.78M | -40.4% |
| Q1 FY2019 | Mar 31, 2019 | $54.95M | -36.8% |
| Q4 FY2018 | Dec 31, 2018 | $66.15M | +26.0% |
| Q3 FY2018 | Sep 30, 2018 | $76.55M | +62.6% |
| Q2 FY2018 | Jun 30, 2018 | $81.89M | +63.7% |
| Q1 FY2018 | Mar 31, 2018 | $86.99M | +50.5% |
| Q4 FY2017 | Dec 31, 2017 | $52.48M | +112.0% |
| Q3 FY2017 | Sep 30, 2017 | $47.08M | +524.3% |
| Q2 FY2017 | Jun 30, 2017 | $50.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $57.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $24.76M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.54M | – |
See a number that looks wrong?